|
Upcoming Events
Tuesday, September 24, 2013 | 8:30 AM - 4:30 PM
Speakers: Elena V. Galkina (Eastern Virginia Medical School), Emmanuel L. Gautier (Washington University School of Medicine, St. Louis), Klaus Ley (La Jolla Institute for Allergy and Immunology), Andrew H. Lichtman (Brigham and Women's Hospital, Harvard Medical School), Kathryn J. Moore (New York University Medical Center), Matthias Nahrendorf (Harvard Medical School), Alan R. Tall (Columbia University Medical Center)
Currently available therapies fail to resolve the full burden of many cardiovascular diseases. Understanding the role of key hematopoietic and inflammatory players in this disease process may help identify new targets for fighting atherosclerosis.
Friday, October 4, 2013 | 8:30 AM - 4:30 PM
Speakers: David Artis (University of Pennsylvania), Stephen M. Collins (McMaster University), Michael A. Fischbach (University of California, San Francisco), Dirk Gevers (The Broad Institute of MIT and Harvard), Jeremy K. Nicholson (Imperial College London), Lita M. Proctor (National Human Genome Research Institute, NIH)
Symbioses between humans and our gut microbiome influence human biology including nutrition, immune function, and brain development. We review how symbiotic relationships impact drug metabolism and development, and a variety of disease states. This symposium features a poster session.
Tuesday, October 22, 2013 | 8:30 AM - 4:30 PM
Speakers: Yasmina Bauer (Actelion Pharmaceuticals Ltd), Jeremy S. Duffield (University of Washington), Raghu Kalluri (The University of Texas MD Anderson Cancer Center), Marco Prunotto (F. Hoffmann-La Roche), Richard M. Silver (Medical University of South Carolina), Dianqing (Dan) Wu (Yale University)
Fibrosis is common in chronic organ injury, leading to progressive life-threatening outcomes. We review the link between fibrosis and disease and explore ways to use biomarkers and imaging to translate laboratory results into clinical success.
Past Events
Friday, May 24, 2013 | 8:30 AM - 4:30 PM
Speakers: Scott A. Armstrong (Memorial Sloan-Kettering Cancer Center), Stephen Baylin (The Johns Hopkins University School of Medicine), Robert A. Copeland (Epizyme, Inc.), Vicki L. Goodman (GlaxoSmithKline), Haitao Li (Tsinghua University, China), X. Shirley Liu (Dana-Farber Cancer Institute), Robert Sims (Constellation Pharmaceuticals, Inc.), Alexander Tarakhovsky (The Rockefeller University)
Epigenetic research has shown that heritable changes in cancer cell transformation occur beyond the primary DNA sequence. This symposium reviews epigenetic regulators in cancer development and progress in designing therapies targeting the epigenome.
Tuesday, April 23, 2013 | 12:00 PM - 4:00 PM
Speakers: Suzanne M. de la Monte (Brown University), William H. Frey II (Alzheimer's Research Center, Regions Hospital, St. Paul, MN), José A. Luchsinger (Columbia University Medical Center), Mark P. Mattson (National Institute on Aging, NIH), Ewan C. McNay (University at Albany, SUNY), Konrad Talbot (University of Pennsylvania)
Organizers: Mercedes Beyna (Pfizer Global Research and Development), Cathleen Gonzales (Pfizer Global Research and Development), Barbara Petrack (Drew University), Jennifer Henry (The New York Academy of Sciences)
Insulin resistance and dysregulated insulin signaling are observed in brains of Alzheimer's patients. Current diabetes drugs that improve cognition and brain insulin signaling in rodents are in clinical trials for mild cognitive impairment and AD.
Monday, March 25, 2013 | 12:00 PM - 4:00 PM
Organizers: Robert Martone (Covance Biomarker Center of Excellence), Harald Murck (Covance Neuroscience Medical and Scientific Services), Jennifer Henry (The New York Academy of Sciences)
Speakers: Ron Duman (Yale University), Guosong Liu (Tsinghua University, China), Jorge Quiroz (Roche), Simone Sartori (University of Innsbruck, Austria), Carlos Zarate (National Institute of Mental Health, NIH)
Major depression is a devastating illness; current therapies based upon monoamine neurotransmitters are beneficial for only one in ten patients. This program reviews a paradigm shift in treatment targeting the glutamatergic neurotransmitter system.
Tuesday, January 22, 2013 | 8:30 AM - 5:30 PM
Organizers: Joshua F. Apgar (Boehringer Ingelheim Pharmaceuticals), Henry Kao (Lundbeck Research USA), Anthony Slavin (Boehringer Ingelheim Pharmaceuticals), Roland Staal (Lundbeck Research USA), Jennifer Henry (The New York Academy of Sciences)
Speakers: Stanley H. Appel (Methodist Neurological Institute), Britta Engelhardt (Universität Bern, Switzerland), Karl Frei (University Hospital Zurich, Switzerland), Howard E. Gendelman (University of Nebraska Medical Center), Christopher A. Hunter (University of Pennsylvania), Michal Schwartz (Weizmann Institute of Science, Israel), Lawrence Steinman (Stanford University), Kevin J. Tracey (Feinstein Institute of Medical Research)
Though no longer regarded as immune-privileged, the role of T cells in the CNS is still not well understood. Experts will discuss the role of T cells in CNS diseases with high unmet medical need, and offer clues to potential intervention.
Tuesday, December 11, 2012 | 8:30 AM - 4:30 PM
Speakers: Albert-László Barabási (Northeastern University), Alessandra Cesano (Nodality), Joel Dudley (Mt Sinai School of Medicine), Manuel Duval (Enumeral Biomedical Corp.), Greg Findlay (Samuel Lunenfeld Research Institute), Alison O'Mahony (Bioseek, a division of DiscoveRx)
The most pressing unmet medical needs correspond to complex diseases caused by a combination of genetic and environmental factors. This symposium discusses the use of biological assays that feature multiple target approaches during the primary discovery steps.
Tuesday, October 23, 2012 | 8:30 AM - 5:00 PM
Organizers: Robert Martone (Covance Biomarker Center of Excellence), Heather Shih (Pfizer External Research Solutions), Mohammad Tabrizi (Merck Research Laboratory), Jennifer Henry, PhD, The New York Academy of Sciences
Speakers: Anthony Coyle (Pfizer), David Hilbert (Zyngenia), Serge Muyldermans (Vrijie Universiteit Brussel, Belgium), Carl Nathan (Weill Cornell Medical College), Mohammad Tabrizi (Merck Research Laboratory), K. Dane Wittrup (Massachusetts Institute of Technology), Anna Wu (University of California, Los Angeles)
There are many monoclonal antibody therapeutics on the market, and myriad development candidates. We review the application of cutting-edge technologies to the development of next-generation antibody therapeutics and address translational challenges.
Tuesday, September 25, 2012 | 8:30 AM - 5:00 PM
Organizers: Zdenek Berger (Pfizer), Mercedes Beyna (Pfizer), Warren Hirst (Pfizer), Jennifer Henry (The New York Academy of Sciences)
Speakers: Zdenek Berger (Pfizer), Ana Maria Cuervo (Albert Einstein College of Medicine), Daniel J. Klionsky (University of Michigan), Beth Levine (University of Texas Southwestern Medical Center), Ralph A. Nixon (Nathan Kline Institute), Eileen P. White (Rutgers University), Richard J. Youle (NINDS), Zhenyu Yue (Mount Sinai School of Medicine)
Autophagy is a route for degradation of aggregated cellular proteins and dysfunctional organelles. This symposium reviews molecular mechanisms of impairment, and discusses drug discovery strategies for modulating autophagy for therapeutic benefits.
Tuesday, May 15, 2012 | 12:00 PM - 5:00 PM
Organizers: Eyal Talor (CEL-SCI Corporation), George Zavoico (MLV), Jennifer Henry (The New York Academy of Sciences)
Speakers: Francesco Marincola (National Institutes of Health), Sangkon Oh (Institute of Immunology Research), Andrew T. Parsa (University of California, San Francisco), Rachel L. Sabado (NYU Langone Medical Center), Eyal Talor (CEL-SCI Corporation), and John S. Yu (Cedars-Sinai Medical Center and Immunocellular Therapeutics, Ltd.)
Cancer vaccines target specific tumor antigens yet spare the immune suppressive effects of radiation and chemotherapy. This symposium reviews the current approaches in cancer immunotherapy, immunomodulation, and highlights emerging cancer vaccines.
Tuesday, April 24, 2012 | 9:00 AM - 5:00 PM
Organizers: Mercedes Beyna (Pfizer), Cheng Chang (Pfizer), Anis Khan (Merck), Tristan Maurer (Pfizer), Jennifer Henry (The New York Academy of Sciences)
Speakers: Cheng Chang (Pfizer), James M. Gallo (Mount Sinai School of Medicine), Donald E. Mager (State University of New York at Buffalo), Tristan Maurer (Pfizer), Matthew Onsum (Merrimack Pharmaceuticals), Eric Stefanich (Genentech, Inc.), Dane Wittrup (MIT), Ramprasad Ramakrishna (Novartis Institues for BioMedical Research)
Modeling and simulation are critical in systematically integrating diverse preclinical information to predict clinical response. In this symposium, guiding principles and specific applications in quantitative translational research will be reviewed.
Tuesday, March 27, 2012 | 1:00 PM - 5:00 PM
Organizers: Seongeun (Julia) Cho (US Food and Drug Administration), Jennifer Henry (The New York Academy of Sciences)
Speakers: Darrell R. Abernethy (US Food and Drug Administration), Angela Birnbaum (University of Minnesota), Jenny Y. Chien (Eli Lilly and Company), Jeremy D. Walston (Johns Hopkins University School of Medicine), Molly E. Zimmerman (Albert Einstein College of Medicine)
Older individuals are the major users of many medications, yet clinical data to support evidence-based therapy are often lacking. This symposium presents clinical, regulatory and industry considerations in investigating drugs for older patients.
Tuesday, February 28, 2012 | 1:00 PM - 5:00 PM
Organizers: Andrew Alt (Bristol-Myers Squibb), Jennifer Henry (The New York Academy of Sciences)
Speakers: P. Jeffrey Conn (Vanderbilt University), Christian Felder (Eli Lilly and Company), Adam Hendricson (Bristol-Myers Squibb), Celine Valant (Monash University, Victoria, Australia)
Allosteric modulation of GPCRs as a therapeutic strategy offers improved selectivity and safety. This symposium discusses emerging screening strategies for allosteric modulators and in vitro assessment of allosteric modulator activity.
Tuesday, January 24, 2012 | 1:00 PM - 5:00 PM
Speakers: Brian T. Gold (University of Kentucky), Simon Lovestone (MRC Centre for Neurodegeneration Research, London), John C. Morris (Washington University School of Medicine), John Olichney (University of California, Davis), and Reisa Sperling (Brigham and Women's Hospital and Harvard Medical School)
New clinical tools suggest that events underlying AD begin many years prior to diagnosis. This symposium explores these structural, functional, and biochemical events that precede and may predict both AD and amnestic mild cognitive impairment (aMCI).
Tuesday, December 6, 2011 | 9:00 AM - 5:00 PM
Organizers: Robert Martone (Covance Biomarker Center of Excellence), Sean Pintchovski (Lundbeck Research USA), and Roland Staal (Lundbeck Research USA), Jennifer Henry (The New York Academy of Sciences)
This symposium gathers experts on microglia and monocyte biology to discuss the role of inflammation in neurological diseases and disorders, insights into their biology, and possible therapeutic interventions.
Tuesday, October 25, 2011 | 9:00 AM - 5:00 PM
Keynote speaker: David Begley (King's College London)
Speakers: Adam Chodobski (The Warren Alpert Medical School of Brown University), William H. Frey II (HealthPartners Alzheimer's Research Center), Damir Janigro (Cleveland Clinic), Brian Kaspar (Research Institute at Nationwide Children's Hospital), Elisa Konofagou (Columbia University), and Joel Pachter (University of Connecticut Health Center)
Barriers protect the brain from toxins and infection, and maintain ionic and volumetric environments. Inefficient function can limit the treatment of neurological diseases. This symposium covers scientific advances and tackles therapeutic challenges.
Tuesday, September 20, 2011 | 1:00 PM - 5:00 PM
Speakers: Charles R. Cantor (Sequenom Inc.), Mark R. Chance (Case Western Reserve University), Randy L. Jirtle (Duke University Medical Center), and Marc Ladanyi (Memorial Sloan-Kettering Cancer Center)
Clinical researchers are investigating strategies to tailor disease treatments to each patient. This symposium reviews state-of-the-art research, translational medical research data, and new technologies to make personalized medicine a reality.
Tuesday, May 24, 2011 | 9:00 AM - 5:00 PM
Organizers: Kelly Bales and Mercedes Beyna (Pfizer), Roland Staal (Lundbeck Research USA), and Jennifer Henry (The New York Academy of Sciences)
Alzheimer's disease is the most common cause of dementia in the elderly. This symposium brings together experts to discuss the role of ApoE4 in Alzheimer's disease (AD), and to discuss potential strategies for prevention and treatment of AD.
Tuesday, April 26, 2011 | 9:00 AM - 5:00 PM
Organizers: Robert H. Ring (Pfizer), Daniel G. Smith (Pfizer), Mercedes E. A. Beyna (Pfizer), and Jennifer S. Henry (The New York Academy of Sciences)
Autism spectrum disorders have wide-ranging symptoms, including impaired social interactions, communication deficits, repetitive behaviors and restricted interests. This symposium explores emerging research in the development of novel therapeutics.
Tuesday, March 22, 2011 | 1:00 PM - 5:00 PM
Speakers: Ron R. Kopito (Stanford University), Eliezer Masliah(UCSD), Pamela J. McLean (Mass General Institute of Neurodegenerative Disease), Stephen M. Strittmatter (Yale University School of Medicine) and X. William Yang (David Geffen School of Medicine at UCLA)
Protein misfolding causes many neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's. This symposium reviews breakthroughs in characteristic non-autonomous disease propagation, and reviews the development of novel therapies.
Tuesday, February 22, 2011 | 1:00 PM - 5:00 PM
Speakers: Johan Auwerx (Ecole Polytechnique Fédérale Lausanne), Leonard Guarente (MIT), Anthony Sauve (Weill Cornell Medical College), David Sinclair (Harvard University), and Eric Verdin (University of California, San Francisco)
Sirtuins are implicated in aging and adaptations to food intake, thus play an important role in low-calorie diets. The symposium reveals discoveries in how sirtuins regulate biological processes, and modulation of their biochemical properties.
Tuesday, January 25, 2011 | 1:00 PM - 5:00 PM
Speakers: Per Gjorstrup (Resolvyx Pharmaceuticals), Karsten Gronert (University of California, Berkeley), Mauro Perretti (Queen Mary University of London), Charles N. Serhan (Harvard University, Brigham & Women's Hospital), Ira Tabas (Columbia University), and Edward Thorp (Columbia University)
Chronic inflammation contributes to the progression of many common diseases. This symposium reviews advances in treating chronic inflammatory diseases by promoting active resolution of inflammation instead of only blocking proinflammatory mediators. Presented as part of the Translational Medicine Initiative.
Steering Committee
|
Bristol-Myers Squibb
Cochair
|
Boehringer Ingelheim
|
|
Pfizer
|
Otsuka America Pharmaceutical, Inc.
|
Ahmad Fawzi, PhD
GPCR BioSciences Inc.
|
Boehringer Ingelheim
|
|
Weill Cornell Medical College
Cochair
|
Boehringer-Ingelheim
|
|
Bristol-Myers Squibb
Secretary
|
Boehringer Ingelheim
|
|
Forest Research Institute
|
Novartis Pharmaceuticals
|
|
Boehringer Ingelheim
|
Charles Lunn, PhD
|
|
Covance Biomarker Center of Excellence
|
Martha Matteo, PhD
|
|
Drew University
|
Pat Rose, PhD
|
|
AstraZeneca Pharmaceuticals LP
|
June Sonnenberg-Reines, PhD
|
|
Lundbeck Research USA
|
Edward Tamer, PhD
|
|
Novartis Institutes for BioMedical Research
|
Intra-Cellular Therapies Inc.
|
|
MLV
|
Sponsors
The Biochemical Pharmacology Discussion Group is proudly supported by:
Mission Partner support for the Frontiers of Science program provided by 
Get more information about how you can sponsor a discussion group.
|
|